Intrasense, a French expert in medical imaging solutions facilitating and securing diagnosis, decision-making, and treatment follow-up, announces the publication of its 2025 half-year results and progress on its strategic roadmap. These accounts were approved on September 24, 2025, by the Board of Directors.

Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), a French expert in AI-enhanced medical imaging solutions that facilitate diagnostics, decision-making, and therapeutic follow-up, announces the CE marking under MDR (Medical Device Regulation) for DUOnco™ Pancreas, marking a new milestone in its innovation strategy focused on oncology follow-up.

Intrasense, a French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnosis, decision-making, and therapeutic follow-up, announces its consolidated sales for the first half of fiscal year 2025.

Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), a French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnostics, decision-making, and therapeutic follow-up, provides an update on its activities two months after announcing its strategic roadmap

Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), the French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnosis, decision-making and therapeutic follow-up (the “Company”), announces a change in the composition of its Board of Directors